Could menopause drug fezolinetant show promise for vasomotor symptoms associated with androgen deprivation therapy?
作者信息
Qin Kirby R, Mertens Eveline, Tempo Jake A, Perera Marlon, Brennan Janelle
机构信息
Department of Urology, Bendigo Health, Bendigo, VIC, Australia.
School of Rural Health, Monash University, Bendigo, VIC, Australia.
出版信息
Transl Androl Urol. 2024 May 31;13(5):920-922. doi: 10.21037/tau-24-12. Epub 2024 May 15.
Abstract
摘要
相似文献
1
Could menopause drug fezolinetant show promise for vasomotor symptoms associated with androgen deprivation therapy?
Transl Androl Urol. 2024 May 31;13(5):920-922. doi: 10.21037/tau-24-12. Epub 2024 May 15.
2
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13.
3
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.
J Pharm Technol. 2023 Dec;39(6):291-297. doi: 10.1177/87551225231198700. Epub 2023 Sep 16.
4
Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Eur J Obstet Gynecol Reprod Biol. 2024 Jun;297:142-152. doi: 10.1016/j.ejogrb.2024.04.017. Epub 2024 Apr 15.
5
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Obstet Gynecol. 2023 Apr 1;141(4):737-747. doi: 10.1097/AOG.0000000000005114. Epub 2023 Mar 9.
6
Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
Eur J Pharmacol. 2021 Aug 15;905:174207. doi: 10.1016/j.ejphar.2021.174207. Epub 2021 May 25.
7
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Menopause. 2024 Jan 1;31(1):68-76. doi: 10.1097/GME.0000000000002281. Epub 2023 Nov 27.
8
Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
touchREV Endocrinol. 2023 Nov;19(2):69-72. doi: 10.17925/EE.2023.19.2.13. Epub 2023 Jun 15.
9
A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.
Nurs Womens Health. 2024 Feb;28(1):80-84. doi: 10.1016/j.nwh.2023.11.005. Epub 2023 Dec 28.
10
Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Menopause. 2020 Dec;27(12):1350-1356. doi: 10.1097/GME.0000000000001621.
本文引用的文献
1
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13.
2
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Obstet Gynecol. 2023 Apr 1;141(4):737-747. doi: 10.1097/AOG.0000000000005114. Epub 2023 Mar 9.
3
Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial.
Eur J Endocrinol. 2022 Nov 1;187(5):617-627. doi: 10.1530/EJE-22-0318.
4
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
J Clin Endocrinol Metab. 2023 Jul 14;108(8):1981-1997. doi: 10.1210/clinem/dgad058.
5
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
Prostate. 2020 May;80(6):527-544. doi: 10.1002/pros.23967. Epub 2020 Mar 4.
6
Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression.
Sci Rep. 2018 Jul 27;8(1):11358. doi: 10.1038/s41598-018-29520-5.
7
A Neural Circuit Underlying the Generation of Hot Flushes.
Cell Rep. 2018 Jul 10;24(2):271-277. doi: 10.1016/j.celrep.2018.06.037.
8
International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.
ESMO Open. 2016 Mar 18;1(2):e000040. doi: 10.1136/esmoopen-2016-000040. eCollection 2016.
9
Effects of Testosterone and Estradiol Deficiency on Vasomotor Symptoms in Hypogonadal Men.
J Clin Endocrinol Metab. 2016 Sep;101(9):3479-86. doi: 10.1210/jc.2016-1612. Epub 2016 Jun 14.
10
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
Lancet Oncol. 2010 Feb;11(2):147-54. doi: 10.1016/S1470-2045(09)70338-9. Epub 2009 Dec 4.
Zotero 插件